Inborn errors of metabolism:
Indications for: OXLUMO
Treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels.
Adults and Children:
Give by SC inj into abdomen, thigh, or upper arms; rotate inj sites. <10kg: loading dose: 6mg/kg once monthly for 3 doses; maintenance (begin 1 month after the last loading dose): 3mg/kg once monthly. 10–<20kg: loading dose: 6mg/kg once monthly for 3 doses; maintenance (begin 1 month after the last loading dose): 6mg/kg once every 3 months. ≥20kg: loading dose: 3mg/kg once monthly for 3 doses; maintenance (begin 1 month after the last loading dose): 3mg/kg once every 3 months. Hemodialysis patients: administer dose after session if given on dialysis days.
OXLUMO Warnings/Precautions:
Severe hepatic impairment (total bilirubin >3×ULN with any AST) or peritoneal dialysis patients: not studied. Pregnancy. Nursing mothers.
OXLUMO Classification:
HAO1-directed small interfering ribonucleic acid.
Adverse Reactions:
Inj site reactions, abdominal pain.
Generic Drug Availability:
NO
How Supplied:
Single-dose vial—1
